EssilorLuxottica set to acquire Optegra clinics

(Image Credit: AdobeStock/Arnéll Koegelenberg/peopleimages.com)

EssilorLuxottica and MidEuropa recently entered into an agreement that will allow EssilorLuxottica to acquire Optegra, an ophthalmology platform operating in the 5 European markets of the Czech Republic, Poland, Slovakia, the Netherlands, and the UK.¹ The acquisition aids in EssilorLuxottica building upon its med-tech strategy, according to a news release.

The transaction is expected to close later in 2025 pending regulatory approvals, in addition to other customary closing conditions.¹

“With the acquisition of Optegra, we are stepping into a new frontier—one where comprehensive eye care, advanced diagnostics, therapeutic interventions, and surgical treatments come together in one seamless platform,” commented Francesco Milleri, chairman and CEO; and Paul du Saillant, deputy CEO at EssilorLuxottica; in the release. “We have the strategic assets to fuel this vision: an extensive distribution network with new clinical approaches, a smart eyewear offering with health care potential, and diagnostic capabilities that will be able to detect conditions ranging from neurodegenerative diseases to cardiovascular dysfunction. Optegra and its experienced doctors will bring new medical capabilities to our Group, enabling us to address patients’ needs with the most advanced vision care technologies and treatments in one trusted system that will anchor our med-tech aspirations. Powered by our growing AI and big data capabilities, we will be able to broaden our impact and deliver the most personalized and seamless patient journey.”

Under the Optegra, Lexum, and Iris brands, the Optegra group operates a network of more than 70 eye hospitals and diagnostic facilities across Europe. These facilities provide ophthalmic treatments and elective vision correction procedures supported by artificial intelligence in pre- and post-op stages. These procedures include cataract surgery, age-related macular degeneration and glaucoma treatments, refractive lens replacement, and laser eye surgery.¹

“Optegra’s evolution under MidEuropa’s ownership reflects our approach to supporting high-quality European health care platforms with strong growth potential. We partnered with Peter Byloos and his experienced leadership team to accelerate the company’s organic expansion and successfully entered 2 new markets, the Netherlands and Slovakia,” said Robert Knorr, managing partner at MidEuropa, in the release. “We supported the opening of new clinics in the UK and completed 8 strategic add-on acquisitions across 5 countries. We are proud to have contributed to Optegra’s digitalization, implementation of AI technologies, and broader mission to expand access to high-quality eye care. We would like to thank the management team and clinical staff for their dedication and ambition throughout this journey. We believe EssilorLuxottica is the ideal partner to lead Optegra into its next phase of growth and innovation, and we wish them every success as they build on the strong foundation we have helped create.”

“Joining forces with EssilorLuxottica marks a transformative chapter for Optegra. Their global leadership in vision care, combined with our clinical excellence and patient-centric approach, creates an innovative platform to redefine the paradigm of ophthalmic services,” said Peter Byloos, MD, CEO of Optegra Eye Health Care, in the release. “This partnership not only accelerates our growth potential but also enhances our ability to deliver advanced, digital, and integrated eye care solutions to all our patients. It also creates a significant opportunity for our clinical team, our staff, and leadership to be part of a global and inspiring leader in vision care.”

Reference:

1. EssilorLuxottica to acquire Optegra clinics, another leap forward in its med-tech strategy. News release. EssilorLuxottica. May 30, 2025. Accessed June 9, 2025. https://www.essilorluxottica.com/en/newsroom/press-releases/essilorluxottica-to-acquire-optegra-clinics/